Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
Alaunos Therapeutics completed its acquisition of Velaris Therapeutics, a privately-held biotech with a PAH pipeline of ActRII-Fc ligand traps (VLR199, VLR247, VLR258) and the anti-PDGF-B antibody VLR360. A concurrent, oversubscribed $350 million private placement led by Fairmount gives the company runway into 2029, funding proof-of-concept data for VLR199 and VLR360 and initial regulatory filings for VLR247 and VLR258, with VLR199 proof-of-concept expected in 2028.
Key figures
- Deal Value Usd
- $350 million (gross proceeds of concurrent private placement)
- Runway
- into 2029
- Board control
- Fairmount designees to hold 4 of 5 board seats
- Vlr199 poc data
- 2028
- Shares outstanding post deal
- approximately 358.59 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.